- Ultragenyx Pharmaceutical recently announced that the FDA accepted for review its resubmitted BLA for UX111, an AAV9 gene therapy for Sanfilippo syndrome Type A, setting a PDUFA action date of September 19, 2026 and acknowledging robust long-term neurodevelopmental and biomarker data with an acceptable safety profile.
- This progress, alongside FDA clearance of the IND for UX016 in GNE myopathy, highlights Ultragenyx’s deepening focus on late-stage gene and rare disease therapies backed by external patient-group funding and U.S.-based manufacturing.
- We’ll now examine how the FDA’s acceptance of the UX111 BLA reshapes Ultragenyx’s investment narrative around pipeline progress and future prospects.
AI is about to change healthcare. These 37 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
Ultragenyx Pharmaceutical Investment Narrative Recap
To own Ultragenyx, you have to believe its late stage rare disease and gene therapy portfolio can eventually support a path to profitability despite ongoing losses and regulatory dependence. The FDA’s acceptance of the resubmitted UX111 BLA is a meaningful step because it keeps one of Ultragenyx’s key gene therapy assets on track, but the most important near term catalyst still appears to be the 2026 PDUFA decision for DTX401, while the biggest risk remains sustained cash burn and potential dilution.
The UX016 IND clearance for GNE myopathy is the most relevant companion announcement, because it reinforces Ultragenyx’s effort to broaden its rare disease pipeline beyond UX111 and DTX401. While UX016 is only entering early stage trials and is unlikely to be a near term financial driver, the externally funded design could modestly ease pressure on Ultragenyx’s own cash resources as it advances multiple late stage programs toward regulatory decisions.
Yet behind this progress, investors should be aware that persistent losses and a high cash burn could still...
Read the full narrative on Ultragenyx Pharmaceutical (it's free!)
Ultragenyx Pharmaceutical’s narrative projects $1.3 billion revenue and $69.1 million earnings by 2029.
Uncover how Ultragenyx Pharmaceutical's forecasts yield a $52.45 fair value, a 134% upside to its current price.
Exploring Other Perspectives
Before this UX111 update, the most optimistic analysts were assuming Ultragenyx could reach about US$2.0 billion in revenue and US$312.0 million in earnings by 2028, but this bullish view sits in sharp contrast to concerns about dependence on a small group of risky programs, so the latest FDA news may prompt you to reconsider which side of that wide expectation range you find more convincing.
Explore 2 other fair value estimates on Ultragenyx Pharmaceutical - why the stock might be worth just $52.45!
Reach Your Own Conclusion
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your Ultragenyx Pharmaceutical research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
- Our free Ultragenyx Pharmaceutical research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Ultragenyx Pharmaceutical's overall financial health at a glance.
Looking For Alternative Opportunities?
Every day counts. These free picks are already gaining attention. See them before the crowd does:
- The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 22 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
- Find 62 companies with promising cash flow potential yet trading below their fair value.
- Uncover the next big thing with 31 elite penny stocks that balance risk and reward.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com